RD12014 (liraglutide biosimilar)
/ HEC Pharm
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 27, 2022
A phase I study comparing the pharmacokinetics of the biosimilar (RD12014) with liraglutide (Victoza®) in healthy Chinese male subjects.
(PubMed, Clin Transl Sci)
- "This study demonstrated pharmacokinetic similarity of RD12014 to Victoza® in healthy Chinese male subjects. Safety and immunogenicity profiles were comparable between the two groups."
Journal • P1 data • PK/PD data
March 24, 2022
A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects
(clinicaltrials.gov)
- P1 | N=50 | Completed | Sponsor: Sunshine Lake Pharma Co., Ltd.
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 2
Of
2
Go to page
1